{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:50:58Z","timestamp":1791553858445,"version":"4.3.4"},"reference-count":96,"publisher":"American Chemical Society (ACS)","issue":"10","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Anterior segment ocular inflammatory disorders, including conjunctivitis, keratitis, scleritis, dry eye disease, and anterior uveitis, represent a major cause of visual impairment worldwide. Conventional pharmacological therapies such as antihistamines, corticosteroids, and immunomodulators primarily provide symptomatic relief but are limited by their adverse effects, poor long-term efficacy, and lack of disease-modifying potential. In this review, RNA-based therapeutics are discussed in detail, emerging as promising and targeted approaches for modulating the molecular mechanisms underlying ocular anterior segment inflammatory conditions. These strategies include small interfering RNA (siRNA), short hairpin RNA (shRNA), antisense oligonucleotides (ASOs), messenger RNA (mRNA), microRNA (miRNA), and long noncoding RNA (lncRNA), each offering distinct mechanisms to regulate gene expression and inflammatory signaling pathways. RNA therapeutics enable precise silencing or modulation of key mediators such as cytokines, transcription factors, and immune regulators involved in Th2-driven and immune-mediated inflammatory responses. Recent advances in nanotechnology-based delivery systems, including lipid nanoparticles, polymeric carriers, and viral vectors, have significantly improved RNA stability, bioavailability, and targeted ocular delivery. Despite these advances, challenges such as ocular surface barriers, rapid tear clearance, enzymatic degradation, off-target effects, and potential immunogenicity remain significant hurdles. Overall, RNA-based therapies hold substantial potential as next-generation, disease-modifying treatments for anterior segment inflammatory disorders, including DED, warranting further translational and clinical investigation.<\/jats:p>","DOI":"10.1021\/acsptsci.6c00443","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:07:32Z","timestamp":1790694452000},"page":"2712-2733","source":"Crossref","is-referenced-by-count":0,"title":["Emerging RNA-Based\nTherapeutic Strategies for Inflammatory\nOphthalmic Disorders of the Anterior Segment: Mechanistic Insights\nand Translational Potential"],"prefix":"10.1021","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8492-5016","authenticated-orcid":true,"given":"Alpana","family":"Kumari","sequence":"first","affiliation":[{"name":"University Institute of Allied Health Sciences, Chandigarh University , , Gharuan , , ,","place":["Mohali, Punjab, India, 140413"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Kabra","sequence":"additional","affiliation":[{"name":"University Institute of Pharma Sciences, Chandigarh University , Gharuan , , ,","place":["Mohali, Punjab, India, 140413"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"issue":"1","key":"2026100909104964200_cit1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/398076","article-title":"Ocular Inflammation","volume":"2015","author":"Huerva","year":"2015","journal-title":"Mediators Inflamm."},{"key":"2026100909104964200_cit2","doi-asserted-by":"publisher","DOI":"10.1016\/j.matdes.2022.111277","article-title":"Functionalized\nHydrogels in Ophthalmic Applications: Ocular Inflammation, Corneal\nInjuries, Vitreous Substitutes and Intravitreal Injection","volume":"224","author":"Gong","year":"2022","journal-title":"Mater. Des."},{"issue":"4","key":"2026100909104964200_cit3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3390\/cimb48040367","article-title":"Natural Products Targeting Immune Mechanisms in Ocular Inflammation:\nUveitis and Dry Eye","volume":"48","author":"Lu","year":"2026","journal-title":"Curr. Issues Mol. Biol."},{"issue":"11","key":"2026100909104964200_cit4","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.ophtha.2017.05.012","article-title":"Update on\nthe Management of Infectious\nKeratitis","volume":"124","author":"Austin","year":"2017","journal-title":"Ophthalmology"},{"issue":"3","key":"2026100909104964200_cit5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.survophthal.2018.12.003","article-title":"The Persistent\nDilemma of Microbial Keratitis: Global Burden, Diagnosis, and Antimicrobial\nResistance","volume":"64","author":"Ung","year":"2019","journal-title":"Surv. Ophthalmol."},{"issue":"6","key":"2026100909104964200_cit6","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1136\/bjo.2009.169607","article-title":"Geographic Variations\nin Microbial Keratitis: An Analysis of the Peer-Reviewed Literature","volume":"95","author":"Shah","year":"2011","journal-title":"Br. J. Ophthalmol."},{"issue":"2","key":"2026100909104964200_cit7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/09286580601001347","article-title":"Microbial Keratitis in South India:\nInfluence of Risk Factors, Climate, and Geographical Variation","volume":"14","author":"Bharathi","year":"2007","journal-title":"Ophthalmic Epidemiol."},{"issue":"12","key":"2026100909104964200_cit8","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1001\/jamaophthalmol.2016.4096","article-title":"Mycotic Ulcer\nTreatment Trial II\nGroup. Effect of Oral Voriconazole on Fungal Keratitis in the Mycotic\nUlcer Treatment Trial II (MUTT II): A Randomized Clinical Trial","volume":"134","author":"Prajna","year":"2016","journal-title":"JAMA Ophthalmol."},{"issue":"2","key":"2026100909104964200_cit9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1080\/08923973.2025.2461056","article-title":"Clinical Characteristics, Treatment,\nand Outcomes of Nivolumab-Induced Uveitis","volume":"47","author":"Wu","year":"2025","journal-title":"Immunopharmacol.\nImmunotoxicol."},{"issue":"2","key":"2026100909104964200_cit10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jcjo.2024.07.013","article-title":"Anterior Uveitis\nfor the Comprehensive\nOphthalmologist","volume":"60","author":"Xie","year":"2025","journal-title":"Can. J. Ophthalmol."},{"key":"2026100909104964200_cit11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2025.03.019","article-title":"Epidemiologic\nStudy of Pediatric Uveitis and Its Ophthalmic Complications Using\nthe Korean National Health Insurance Claim Database","volume":"275","author":"Hong","year":"2025","journal-title":"Am. J. Ophthalmol."},{"issue":"1","key":"2026100909104964200_cit12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4103\/0301-4738.58468","article-title":"Current Approach\nin\nDiagnosis and Management of Anterior Uveitis","volume":"58","author":"Agrawal","year":"2010","journal-title":"Indian J. Ophthalmol."},{"key":"2026100909104964200_cit13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2147\/OPTO.S72079","article-title":"Diagnosis and Treatment\nof Anterior Uveitis: Optometric Management","volume":"8","author":"Harthan","year":"2016","journal-title":"Clin. Optom."},{"issue":"6","key":"2026100909104964200_cit14","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/ceo.13761","article-title":"Epidemiology\nof Episcleritis and Scleritis in Urban Australia","volume":"48","author":"Thong","year":"2020","journal-title":"Clin. Experiment. Ophthalmol."},{"issue":"12","key":"2026100909104964200_cit15","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1097\/ICO.0b013e3182a407c3","article-title":"Incidence\nand Prevalence of Episcleritis\nand Scleritis in Northern California","volume":"32","author":"Honik","year":"2013","journal-title":"Cornea"},{"issue":"4","key":"2026100909104964200_cit16","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40266-024-01105-0","article-title":"Management of Scleritis\nin Older Adults","volume":"41","author":"Butler","year":"2024","journal-title":"Drugs Aging"},{"key":"2026100909104964200_cit17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ajo.2025.05.028","article-title":"Incidence\nand Prevalence of Scleritis Subtypes and Associated Ocular Complications\nin the TriNetX Database","volume":"277","author":"Spangler","year":"2025","journal-title":"Am. J. Ophthalmol."},{"issue":"6","key":"2026100909104964200_cit18","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3390\/life14060650","article-title":"Allergic Conjunctivitis:\nReview of Current Types, Treatments, and Trends","volume":"14","author":"Tariq","year":"2024","journal-title":"Life"},{"issue":"1","key":"2026100909104964200_cit19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s12016-025-09098-3","article-title":"Decoding Allergic Conjunctivitis:\nLatest Perspectives on Etiological Drivers and Immunopathological\nMechanisms","volume":"68","author":"Bao","year":"2025","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"1","key":"2026100909104964200_cit20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4274\/tjo.galenos.2020.11456","article-title":"Current\nKnowledge in Allergic Conjunctivitis","volume":"51","author":"Villegas","year":"2021","journal-title":"Turk.\nJ. Ophthalmol."},{"issue":"11","key":"2026100909104964200_cit21","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s00347-017-0580-1","article-title":"[Seasonal allergic\nconjunctivitis]","volume":"114","author":"Schro\u0308der","year":"2017","journal-title":"Ophthalmol. Z. Dtsch. Ophthalmol.\nGes."},{"issue":"2","key":"2026100909104964200_cit22","doi-asserted-by":"publisher","first-page":"118","DOI":"10.2174\/187221309788489733","article-title":"Seasonal and\nPerennial Allergic Conjunctivitis","volume":"3","author":"Wong","year":"2009","journal-title":"Recent Pat.\nInflamm. Allergy Drug Discovery"},{"issue":"3","key":"2026100909104964200_cit23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.survophthal.2018.12.001","article-title":"Vernal Keratoconjunctivitis","volume":"64","author":"Singhal","year":"2019","journal-title":"Surv. Ophthalmol."},{"issue":"5","key":"2026100909104964200_cit24","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1055\/a-2244-2885","article-title":"Atopic\nKeratoconjunctivitis: Pathophysiology, Clinic, and Potential New Therapeutic\nConcepts","volume":"241","author":"Lapp","year":"2024","journal-title":"Klin. Monatsbl. Augenheilkd."},{"issue":"5","key":"2026100909104964200_cit25","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1055\/s-0034-1368334","article-title":"[Giant papillary\nconjunctivitis]","volume":"231","author":"Bischoff","year":"2014","journal-title":"Klin. Monatsbl. Augenheilkd."},{"issue":"2","key":"2026100909104964200_cit26","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.survophthal.2022.06.003","article-title":"The Inflammasome\nPathway: A Key Player in Ocular Surface and Anterior Segment Diseases","volume":"68","author":"Mandell","year":"2023","journal-title":"Surv. Ophthalmol."},{"key":"2026100909104964200_cit27","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2026.1863898","article-title":"Pathophysiological\nand Molecular Insights into Allergic Conjunctivitis: An Expanding\nAnalysis of Immunological Endotypes","volume":"7","author":"Velazquez-Soto","year":"2026","journal-title":"Front.\nAllergy"},{"issue":"1","key":"2026100909104964200_cit28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nrm2321","article-title":"Argonaute Proteins:\nKey Players in RNA Silencing","volume":"9","author":"Hutvagner","year":"2008","journal-title":"Nat. Rev. Mol.\nCell Biol."},{"issue":"1","key":"2026100909104964200_cit29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27493-0","article-title":"An Ionizable Lipid Toolbox for RNA\nDelivery","volume":"12","author":"Han","year":"2021","journal-title":"Nat. Commun."},{"key":"2026100909104964200_cit30","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6691291","article-title":"Immunogenetics\nof the Ocular Anterior\nSegment: Lessons from Inherited Disorders","volume":"2021","author":"Serpen","year":"2021","journal-title":"J.\nOphthalmol."},{"issue":"16","key":"2026100909104964200_cit31","doi-asserted-by":"publisher","first-page":"9354","DOI":"10.3390\/ijms23169354","article-title":"Expression of MicroRNAs in Sepsis-Related\nOrgan Dysfunction: A Systematic Review","volume":"23","author":"Maiese","year":"2022","journal-title":"Int.\nJ. Mol. Sci."},{"issue":"8","key":"2026100909104964200_cit32","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1517\/14656566.2015.1040760","article-title":"Advances\nin Pharmacotherapy for Allergic Conjunctivitis","volume":"16","author":"Abelson","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"issue":"5","key":"2026100909104964200_cit33","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/ACI.0000000000000473","article-title":"Topical Antihistamines,\nMast Cell Stabilizers, and\nDual-Action Agents in Ocular Allergy: Current Trends","volume":"18","author":"Ben-Eli","year":"2018","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"issue":"2","key":"2026100909104964200_cit34","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0091-6749(98)70094-6","article-title":"A Randomized, Double-Masked,\nPlacebo-Controlled Parallel Study of\n0.2% Loteprednol Etabonate in Patients with Seasonal Allergic Conjunctivitis","volume":"102","author":"Dell","year":"1998","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"2026100909104964200_cit35","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/ACI.0b013e32833dfa28","article-title":"Treatment\nof Seasonal Allergic Conjunctivitis\nwith Ophthalmic Corticosteroids: In Search of the Perfect Ocular Corticosteroids\nin the Treatment of Allergic Conjunctivitis","volume":"10","author":"Bielory","year":"2010","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"2026100909104964200_cit36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13223-020-0403-9","article-title":"A Contemporary Look\nat Allergic Conjunctivitis","volume":"16","author":"Dupuis","year":"2020","journal-title":"Allergy Asthma Clin.\nImmunol."},{"issue":"1","key":"2026100909104964200_cit37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13223-021-00513-w","article-title":"Long-Term\nOutcomes of 0.1% Tacrolimus Eye Drops in Eyes with Severe Allergic\nConjunctival Diseases","volume":"17","author":"Yazu","year":"2021","journal-title":"Allergy Asthma Clin.\nImmunol."},{"issue":"4","key":"2026100909104964200_cit38","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/14656566.2018.1439920","article-title":"Loteprednol Etabonate for Inflammatory Conditions of\nthe Anterior Segment of the Eye: Twenty Years of Clinical Experience\nwith a Retrometabolically Designed Corticosteroid","volume":"19","author":"Comstock","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"issue":"4","key":"2026100909104964200_cit39","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1097\/ACI.0000000000000669","article-title":"The Allergic Eye: Recommendations\nabout Pharmacotherapy\nand Recent Therapeutic Agents","volume":"20","author":"Kimchi","year":"2020","journal-title":"Curr. Opin. Allergy\nClin. Immunol."},{"issue":"6","key":"2026100909104964200_cit40","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1615\/CritRevImmunol.v29.i6.10","article-title":"Regulation of Allergy with RNA Interference","volume":"29","author":"Suzuki","year":"2009","journal-title":"Crit. Rev. Immunol."},{"issue":"9","key":"2026100909104964200_cit41","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ni.3771","article-title":"Gene Regulation\nin the Immune System\nby Long Noncoding RNAs","volume":"18","author":"Chen","year":"2017","journal-title":"Nat. Immunol."},{"issue":"16","key":"2026100909104964200_cit42","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.2174\/1389450123666220919122520","article-title":"Long Non-Coding\nRNA Therapeutics: Recent Advances and Challenges","volume":"23","author":"Sangeeth","year":"2022","journal-title":"Curr. Drug Targets"},{"issue":"7","key":"2026100909104964200_cit43","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.3390\/ijms25073630","article-title":"Non-Coding\nRNA-Targeted Therapy: A State-of-the-Art Review","volume":"25","author":"Nappi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"2026100909104964200_cit44","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/j.ophtha.2014.03.038","article-title":"Aganirsen Antisense Oligonucleotide Eye Drops Inhibit Keratitis-Induced\nCorneal Neovascularization and Reduce Need for Transplantation: The\nI-CAN Study","volume":"121","author":"Cursiefen","year":"2014","journal-title":"Ophthalmology"},{"issue":"11","key":"2026100909104964200_cit45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpet.2025.103745","article-title":"Anti-IGF-1R\nAntisense Oligonucleotide\nCT102: A Promising Therapeutic Agent for Graves\u2019 Ophthalmopathy","volume":"392","author":"Zhou","year":"2025","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6","key":"2026100909104964200_cit46","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v29.i6.20","article-title":"In Vivo Delivery\nAspects of miRNA, shRNA and siRNA","volume":"29","author":"Khatri","year":"2012","journal-title":"Crit. Rev.\nTher. Drug Carrier Syst."},{"issue":"4","key":"2026100909104964200_cit47","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/bph.12330","article-title":"Small-Interfering\nRNAs (siRNAs) as\na Promising Tool for Ocular Therapy","volume":"170","author":"Guzman-Aranguez","year":"2013","journal-title":"Br. J.\nPharmacol."},{"key":"2026100909104964200_cit48","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jconrel.2020.07.004","article-title":"Topical\nsiRNA Delivery to the Cornea and Anterior Eye by Hybrid Silicon-Lipid\nNanoparticles","volume":"326","author":"Baran-Rachwalska","year":"2020","journal-title":"J. Controlled Release"},{"issue":"6","key":"2026100909104964200_cit49","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1167\/iovs.11-9139","article-title":"Nanoparticle-Mediated\nDelivery of shRNA.VEGF-A Plasmids Regresses Corneal Neovascularization","volume":"53","author":"Qazi","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"4","key":"2026100909104964200_cit50","doi-asserted-by":"publisher","DOI":"10.1093\/lifemedi\/lnae035","article-title":"mRNA Therapy: A Precise\nand Efficient Approach for Disease Treatment","volume":"3","author":"Zhou","year":"2024","journal-title":"Life Med."},{"issue":"2","key":"2026100909104964200_cit51","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3390\/nano10020364","article-title":"Nanomedicines\nto Deliver mRNA: State\nof the Art and Future Perspectives","volume":"10","author":"Go\u0301mez-Aguado","year":"2020","journal-title":"Nanomaterials"},{"key":"2026100909104964200_cit52","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.848985","article-title":"MicroRNAs in the Regulation\nof Th17\/Treg Homeostasis and Their Potential Role in Uveitis","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Genet."},{"issue":"8","key":"2026100909104964200_cit53","first-page":"1603","article-title":"Influence of miR155\non Allergic Conjunctivitis\nin Mice via Regulation of NF-\u03baB Signal Pathway","volume":"18","author":"Bai","year":"2019","journal-title":"Trop. J. Pharm. Res."},{"issue":"3","key":"2026100909104964200_cit54","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s12033-007-9013-8","article-title":"The microRNA (miRNA):\nOverview of\nthe RNA Genes That Modulate Gene Function","volume":"38","author":"Ying","year":"2008","journal-title":"Mol.\nBiotechnol."},{"issue":"4","key":"2026100909104964200_cit55","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1089\/nat.2019.0838","article-title":"Delivery\nof Antisense Oligonucleotides to the Cornea","volume":"30","author":"Chau","year":"2020","journal-title":"Nucleic Acid Ther."},{"issue":"5","key":"2026100909104964200_cit56","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jid.2019.09.022","article-title":"Allele-Specific Small Interfering\nRNA Corrects Aberrant Cellular Phenotype in Keratitis-Ichthyosis-Deafness\nSyndrome Keratinocytes","volume":"140","author":"Lee","year":"2020","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"2026100909104964200_cit57","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41392-024-02002-z","article-title":"Progress and Prospects of mRNA-Based\nDrugs in Pre-Clinical and Clinical Applications","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"2026100909104964200_cit58","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2021.108482","article-title":"RNA Therapeutics\nin Ophthalmology - Translation to Clinical Trials","volume":"205","author":"Gupta","year":"2021","journal-title":"Exp. Eye Res."},{"issue":"2","key":"2026100909104964200_cit59","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41580-021-00330-4","article-title":"Author Correction:\nGene Regulation by Long Non-Coding RNAs and Its Biological Functions","volume":"22","author":"Statello","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2026100909104964200_cit60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2026.114729","article-title":"Nucleic Acid\nDrug Delivery in Ophthalmology: Emerging Trends and Future Perspectives","volume":"392","author":"Yang","year":"2026","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"issue":"11","key":"2026100909104964200_cit61","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.tibtech.2024.05.002","article-title":"Ocular RNA Nanomedicine: Engineered Delivery Nanoplatforms\nin Treating Eye Diseases","volume":"42","author":"Zhang","year":"2024","journal-title":"Trends Biotechnol."},{"issue":"6","key":"2026100909104964200_cit62","doi-asserted-by":"publisher","first-page":"344","DOI":"10.21037\/atm-22-982","article-title":"MiR-146a Upregulates\nFOXP3 and Suppresses Inflammation by Targeting\nHIPK3\/STAT3 in Allergic Conjunctivitis","volume":"10","author":"Guo","year":"2022","journal-title":"Ann.\nTransl. Med."},{"issue":"13","key":"2026100909104964200_cit63","doi-asserted-by":"publisher","first-page":"7939","DOI":"10.1167\/iovs.15-17619","article-title":"Human Corneal\nMicroRNA Expression Profile in Fungal Keratitis","volume":"56","author":"Boomiraj","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"9","key":"2026100909104964200_cit64","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.2174\/1566524014666141021145909","article-title":"A New Approach\nof Delivering siRNA to the Cornea and Its Application for Inhibiting\nHerpes Simplex Keratitis","volume":"14","author":"Li","year":"2014","journal-title":"Curr. Mol. Med."},{"issue":"5","key":"2026100909104964200_cit65","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1021\/acsinfecdis.5c01053","article-title":"MicroRNA-146a-5p\nNegatively Regulates Inflammation via the Dectin-1\/Syk\/NF-\u03baB\nSignaling Pathway in Aspergillus fumigatus Keratitis","volume":"12","author":"Li","year":"2026","journal-title":"ACS Infect. Dis."},{"key":"2026100909104964200_cit66","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ajo.2025.01.019","article-title":"The Global Epidemiology of Scleritis:\nA Systematic Review and Meta-Analysis","volume":"273","author":"Cifuentes-Gonza\u0301lez","year":"2025","journal-title":"Am. J.\nOphthalmol."},{"key":"2026100909104964200_cit67","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123353","article-title":"MicroRNA-Loaded Antioxidant Nanoplatforms for Prevention and Treatment\nof Experimental Acute and Chronic Uveitis","volume":"322","author":"Sheng","year":"2025","journal-title":"Biomaterials"},{"issue":"2","key":"2026100909104964200_cit68","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/eer3.24","article-title":"Gene Therapy:\nNew and Future Treatments\nfor Uveitis","volume":"1","author":"Yang","year":"2024","journal-title":"Eye ENT Res."},{"issue":"4","key":"2026100909104964200_cit69","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3390\/ijms17040478","article-title":"Novel Insights into the Role of Long\nNoncoding RNA in Ocular Diseases","volume":"17","author":"Li","year":"2016","journal-title":"Int. J. Mol.\nSci."},{"issue":"1","key":"2026100909104964200_cit70","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41420-024-02002-6","article-title":"Roles of Long\nNoncoding RNAs in Human Inflammatory Diseases","volume":"10","author":"Zhang","year":"2024","journal-title":"Cell Death Discovery"},{"issue":"6","key":"2026100909104964200_cit71","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1089\/nat.2023.0044","article-title":"Modulation of Gene\nExpression in the Eye with Antisense Oligonucleotides","volume":"33","author":"Hu","year":"2023","journal-title":"Nucleic Acid Ther."},{"issue":"8","key":"2026100909104964200_cit72","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.3390\/ijms26083456","article-title":"Recent Update\non siRNA Therapeutics","volume":"26","author":"Ebenezer","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"2026100909104964200_cit73","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1186\/1756-0500-7-642","article-title":"CAPN5 Gene Silencing\nby Short Hairpin RNA Interference","volume":"7","author":"Nelson","year":"2014","journal-title":"BMC Res.\nNotes"},{"issue":"4","key":"2026100909104964200_cit74","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2217\/nnm-2018-0278","article-title":"Solid Lipid\nNanoparticles for Ocular Delivery of Isoniazid: Evaluation, Proof\nof Concept and in Vivo Safety & Kinetics","volume":"14","author":"Singh","year":"2019","journal-title":"Nanomedicine"},{"issue":"12","key":"2026100909104964200_cit75","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3390\/pharmaceutics12121232","article-title":"Biodegradable\nNanoparticle for Cornea Drug Delivery: Focus Review","volume":"12","author":"Mobaraki","year":"2020","journal-title":"Pharmaceutics"},{"issue":"22","key":"2026100909104964200_cit76","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212368","article-title":"Nanotechnology for Topical Drug Delivery\nto the Anterior Segment of the Eye","volume":"22","author":"Vaneev","year":"2021","journal-title":"Int. J.\nMol. Sci."},{"issue":"4","key":"2026100909104964200_cit77","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1038\/s41596-025-01243-8","article-title":"Dual AAV Vectors\nfor Efficient Delivery of Large Transgenes","volume":"21","author":"Mittas","year":"2026","journal-title":"Nat. Protoc."},{"issue":"1","key":"2026100909104964200_cit78","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1754-1611-6-7","article-title":"Strategies\nfor Ocular siRNA Delivery: Potential and Limitations of Non-Viral\nNanocarriers","volume":"6","author":"Thakur","year":"2012","journal-title":"J. Biol. Eng."},{"issue":"1","key":"2026100909104964200_cit79","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12951-023-01992-2","article-title":"Nanotechnology-Based\nOcular Drug\nDelivery Systems: Recent Advances and Future Prospects","volume":"21","author":"Li","year":"2023","journal-title":"J. Nanobiotechnology"},{"key":"2026100909104964200_cit80","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3389\/fbioe.2020.00228","article-title":"Hydrogel Biomaterials for Application\nin Ocular Drug\nDelivery","volume":"8","author":"Lynch","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"12","key":"2026100909104964200_cit81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpet.2025.103738","article-title":"Recent Advances\nand Future Challenges in Nanosystems\nfor Ocular Drug Delivery","volume":"392","author":"Shahror","year":"2025","journal-title":"J. Pharmacol. Exp.\nTher."},{"key":"2026100909104964200_cit100","doi-asserted-by":"publisher","first-page":"114370","DOI":"10.1016\/j.intimp.2025.114370","article-title":"MiR-30b-5p ameliorates\nexperimental autoimmune uveitis\nby inhibiting the Atg5\/Atg12\/Becn1 Axis","volume":"151","author":"Liu","year":"2025","journal-title":"International\nImmunopharmacology"},{"key":"2026100909104964200_cit101","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jconrel.2020.07.004","article-title":"Topical\nsiRNA delivery to the cornea and anterior eye\nby hybrid silicon-lipid nanoparticles","volume":"326","author":"Baran-Rachwalska","year":"2020","journal-title":"Journal\nof Controlled Release"},{"issue":"12","key":"2026100909104964200_cit82","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid Nanoparticles\nfor mRNA Delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"issue":"2","key":"2026100909104964200_cit83","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2217\/nnm-2018-0326","article-title":"Controlling Endosomal\nEscape Using Nanoparticle Composition: Current Progress and Future\nPerspectives","volume":"14","author":"Cupic","year":"2019","journal-title":"Nanomedicine"},{"issue":"2","key":"2026100909104964200_cit84","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5497\/wjp.v2.i2.47","article-title":"Ocular Drug Delivery\nSystems: An Overview","volume":"2","author":"Patel","year":"2013","journal-title":"World J. Pharmacol."},{"issue":"4","key":"2026100909104964200_cit85","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3390\/pharmaceutics15041091","article-title":"Intrastromal Injections\nin the Management of Infectious Keratitis","volume":"15","author":"Zemba","year":"2023","journal-title":"Pharmaceutics"},{"issue":"10","key":"2026100909104964200_cit86","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.3390\/pharmaceutics17101305","article-title":"RNA Therapeutics: Delivery\nProblems and Solutions-A Review","volume":"17","author":"Pozdniakova","year":"2025","journal-title":"Pharmaceutics"},{"issue":"6","key":"2026100909104964200_cit87","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.4103\/ijo.IJO_1893_22","article-title":"Nanocarriers for\nOcular Drug Delivery: Recent Advances\nand Future Opportunities","volume":"71","author":"Amrutkar","year":"2023","journal-title":"Indian J. Ophthalmol."},{"key":"2026100909104964200_cit88","unstructured":"Lopez-Fraga, M.; Jimenez, A. I.; Valcarel, T. M.\n          siRNA and Their Use in Methods and Compositions for the Treatment\nand\/or Prevention of Eye Conditions. US9018183B2April 28, 2015. https:\/\/patents.google.com\/patent\/US9018183B2\/fr (accessed 2026\u201308\u201320)."},{"key":"2026100909104964200_cit89","unstructured":"Chatterton, J. E.; Clark, A. F.\n          Transferrin\/Transferrin Receptor-Mediated siRNA Delivery. US9562230B2February 7, 2017. https:\/\/patents.google.com\/patent\/US9562230B2\/en?oq=US9562230B2 (accessed 2026\u201308\u201320)."},{"key":"2026100909104964200_cit90","unstructured":"Rejman, J.\n          \n          Therapeutic Nucleic\nAcid for the Treatment of Ophthalmic Diseases. WO2024230934A1November 14, 2024. https:\/\/patents.google.com\/patent\/WO2024230934A1\/en?oq=WO2024230934A1 (accessed 2026\u201308\u201320)."},{"key":"2026100909104964200_cit91","unstructured":"Sun, D.; RASOOL, S.; SILVA, B. R. D.\n          Methods of Treating\nEye Disease. WO2024220435A1October 24, 2024. https:\/\/patents.google.com\/patent\/WO2024220435A1\/en?oq=WO2024220435A1 (accessed 2026\u201308\u201320)."},{"issue":"4","key":"2026100909104964200_cit92","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/13543784.2018.1457647","article-title":"Tivanisiran, a Novel siRNA for the\nTreatment of Dry Eye Disease","volume":"27","author":"Moreno-Montan\u0303e\u0301s","year":"2018","journal-title":"Expert Opin. Investig.\nDrugs"},{"issue":"6","key":"2026100909104964200_cit93","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.3390\/pharmaceutics15061746","article-title":"Recent Advances\nof Ocular Drug Delivery Systems: Prominence of Ocular Implants for\nChronic Eye Diseases","volume":"15","author":"Mostafa","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026100909104964200_cit94","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13073-017-0450-0","article-title":"Advances\nin the Delivery of RNA Therapeutics:\nFrom Concept to Clinical Reality","volume":"9","author":"Kaczmarek","year":"2017","journal-title":"Genome Med."}],"container-title":["ACS Pharmacology &amp; Translational\nScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsptsci.6c00443","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/aptsfn\/article-pdf\/9\/10\/2712\/68696016\/acsptsci.6c00443.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/aptsfn\/article-pdf\/9\/10\/2712\/68696016\/acsptsci.6c00443.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:12:03Z","timestamp":1791551523000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/aptsfn\/article\/9\/10\/2712\/5441336\/Emerging-RNA-Based-Therapeutic-Strategies-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":96,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,9,29]]},"published-print":{"date-parts":[[2026,10,9]]}},"URL":"https:\/\/doi.org\/10.1021\/acsptsci.6c00443","relation":{},"ISSN":["2575-9108"],"issn-type":[{"value":"2575-9108","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]}}}